메뉴 건너뛰기




Volumn 15, Issue 4, 2008, Pages 408-414

Modern treatment of Hodgkin lymphoma

Author keywords

Fluoro 2 deoxy D glucose positron emission tomography scan; Hodgkin lymphoma; Salvage; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GALIXIMAB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOTOXIN; MDX 060; MELPHALAN; MONOCLONAL ANTIBODY; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SGN 30; SGN 35; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; DIAGNOSTIC AGENT;

EID: 47149117046     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328302c9d8     Document Type: Review
Times cited : (20)

References (56)
  • 1
    • 35848930961 scopus 로고    scopus 로고
    • Hodgkin's disease- From pathology specimen to cure
    • Diehl V. Hodgkin's disease- From pathology specimen to cure. N Engl J Med 2007; 357:1968-1971.
    • (2007) N Engl J Med , vol.357 , pp. 1968-1971
    • Diehl, V.1
  • 2
    • 23044452477 scopus 로고    scopus 로고
    • Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
    • Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642.
    • (2005) J Clin Oncol , vol.23 , pp. 4634-4642
    • Meyer, R.M.1    Gospodarowicz, M.K.2    Connors, J.M.3
  • 3
    • 24944460608 scopus 로고    scopus 로고
    • First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
    • 561s; abstract 6505
    • Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005; 23:561s; abstract 6505.
    • (2005) J Clin Oncol , vol.23
    • Noordijk, E.M.1    Thomas, J.2    Ferme, C.3
  • 4
    • 46749138836 scopus 로고    scopus 로고
    • Doxorubicin, Vinblastine and Gemci-tabine (AVG), a novel regimen excluding Bleomycin for the treatment of early stage Hodgkin lymphoma (HL): Results of CALGB 50203
    • abstract 214
    • Straus D, LaCase A, Juweid M, et al. Doxorubicin, Vinblastine and Gemci-tabine (AVG), a novel regimen excluding Bleomycin for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood 2007; 110:70a; abstract 214.
    • (2007) Blood , vol.110
    • Straus, D.1    LaCase, A.2    Juweid, M.3
  • 5
    • 33646811123 scopus 로고    scopus 로고
    • HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG)
    • 561s; abstract 6506
    • Diehl V, Brillant C, Engert A, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2005; 23:561s; abstract 6506.
    • (2005) J Clin Oncol , vol.23
    • Diehl, V.1    Brillant, C.2    Engert, A.3
  • 6
    • 35848959692 scopus 로고    scopus 로고
    • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    • Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:191 6-1927.
    • (2007) N Engl J Med , vol.357 , Issue.191 , pp. 6-1927
    • Ferme, C.1    Eghbali, H.2    Meerwaldt, J.H.3
  • 7
    • 31144465569 scopus 로고    scopus 로고
    • ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
    • Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23:9198-9207.
    • (2005) J Clin Oncol , vol.23 , pp. 9198-9207
    • Gobbi, P.G.1    Levis, A.2    Chisesi, T.3
  • 8
    • 33644818361 scopus 로고    scopus 로고
    • Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
    • Johnson PWM, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23:9208-9218.
    • (2005) J Clin Oncol , vol.23 , pp. 9208-9218
    • Johnson, P.W.M.1    Radford, J.A.2    Cullen, M.H.3
  • 10
    • 34249285155 scopus 로고    scopus 로고
    • G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis
    • Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137:545-552.
    • (2007) Br J Haematol , vol.137 , pp. 545-552
    • Evens, A.M.1    Cilley, J.2    Ortiz, T.3
  • 11
    • 33847270617 scopus 로고    scopus 로고
    • ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors
    • Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18:376-380.
    • (2007) Ann Oncol , vol.18 , pp. 376-380
    • Boleti, E.1    Mead, G.M.2
  • 12
    • 32944468191 scopus 로고    scopus 로고
    • Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
    • Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614-7620.
    • (2005) J Clin Oncol , vol.23 , pp. 7614-7620
    • Martin, W.G.1    Ristow, K.M.2    Habermann, T.M.3
  • 13
    • 0036467658 scopus 로고    scopus 로고
    • Stanford Vand radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial
    • Horning SJ, Hoppe RT, Breslin S, et al. Stanford Vand radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630-637.
    • (2002) J Clin Oncol , vol.20 , pp. 630-637
    • Horning, S.J.1    Hoppe, R.T.2    Breslin, S.3
  • 14
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3
  • 15
    • 59449100046 scopus 로고    scopus 로고
    • Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group
    • abstract 211
    • Andreas E, Franklin J, Diehl V. Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood 2007; 110:70a; abstract 211.
    • (2007) Blood , vol.110
    • Andreas, E.1    Franklin, J.2    Diehl, V.3
  • 16
    • 0032548107 scopus 로고    scopus 로고
    • A prognostic score for advanced Hodgkin's disease
    • Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
    • (1998) N Engl J Med , vol.339 , pp. 1506-1514
    • Hasenclever, D.1    Diehl, V.2    Armitage, J.O.3
  • 17
    • 68449090699 scopus 로고    scopus 로고
    • Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) Groups and in patients who have PET positive disease after 2 3 cycles of therapy
    • abstract 215
    • Wedgwood AR, Fanale MA, Fayad LE, et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) Groups and in patients who have PET positive disease after 2 3 cycles of therapy. Blood 2007; 110:71a; abstract 215.
    • (2007) Blood , vol.110
    • Wedgwood, A.R.1    Fanale, M.A.2    Fayad, L.E.3
  • 18
    • 37349064204 scopus 로고    scopus 로고
    • Clonotypic B cells circulate in Hodgkin's lymphoma (HL)
    • abstract 470
    • Jones RJ, Lin L, Gocke C, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). Blood 2006; 108:143a; abstract 470.
    • (2006) Blood , vol.108
    • Jones, R.J.1    Lin, L.2    Gocke, C.3
  • 19
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59.
    • (2006) Blood , vol.107 , pp. 52-59
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 20
    • 33645998113 scopus 로고    scopus 로고
    • The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
    • Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
    • (2006) Haematologica , vol.91 , pp. 475-481
    • Gallamini, A.1    Rigacci, L.2    Merli, F.3
  • 21
    • 34548486030 scopus 로고    scopus 로고
    • Early Interim 2-[18F]Fluoro-2- Deoxy-D-Glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish Study
    • Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2- Deoxy-D-Glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish Study. J Clin Oncol 2007; 25:3746-3752.
    • (2007) J Clin Oncol , vol.25 , pp. 3746-3752
    • Gallamini, A.1    Hutchings, M.2    Rigacci, L.3
  • 22
    • 34548541713 scopus 로고    scopus 로고
    • Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
    • Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25:3902-3907.
    • (2007) J Clin Oncol , vol.25 , pp. 3902-3907
    • Advani, R.1    Maeda, L.2    Lavori, P.3
  • 23
    • 33846863991 scopus 로고    scopus 로고
    • Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
    • Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
    • (2007) Blood , vol.109 , pp. 905-909
    • Dann, E.J.1    Bar-Shalom, R.2    Tamir, A.3
  • 24
    • 0027404777 scopus 로고
    • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
    • Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. The Lancet 1993; 341:1051-1054.
    • (1993) The Lancet , vol.341 , pp. 1051-1054
    • Linch, D.C.1    Goldstone, A.H.2    McMillan, A.3
  • 25
    • 66649134821 scopus 로고    scopus 로고
    • Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT), 567s; abstract 6508
    • Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2005; 23:567s; abstract 6508.
    • (2005) J Clin Oncol , vol.23
    • Schmitz, N.1    Haverkamp, H.2    Josting, A.3
  • 26
    • 20944446433 scopus 로고    scopus 로고
    • Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
    • Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625-633.
    • (2005) Ann Oncol , vol.16 , pp. 625-633
    • Sureda, A.1    Constans, M.2    Iriondo, A.3
  • 27
    • 1542359509 scopus 로고    scopus 로고
    • Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
    • Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645-652.
    • (2004) Br J Haematol , vol.124 , pp. 645-652
    • Moskowitz, C.H.1    Kewalramani, T.2    Nimer, S.D.3
  • 28
    • 34249949761 scopus 로고    scopus 로고
    • Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma
    • Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000-2005.
    • (2007) J Clin Oncol , vol.25 , pp. 2000-2005
    • Sieniawski, M.1    Franklin, J.2    Nogova, L.3
  • 29
    • 34447320514 scopus 로고    scopus 로고
    • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    • Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18:1071-1079.
    • (2007) Ann Oncol , vol.18 , pp. 1071-1079
    • Bartlett, N.L.1    Niedzwiecki, D.2    Johnson, J.L.3
  • 30
    • 30744445985 scopus 로고    scopus 로고
    • Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and mel-phalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106:353-360.
    • Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and mel-phalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106:353-360.
  • 31
    • 34250223441 scopus 로고    scopus 로고
    • Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma
    • Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma. Cancer 2007; 109:2481-2489.
    • (2007) Cancer , vol.109 , pp. 2481-2489
    • Jabbour, E.1    Hosing, C.2    Ayers, G.3
  • 32
    • 33846213431 scopus 로고    scopus 로고
    • Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
    • Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486-491.
    • (2007) Blood , vol.109 , pp. 486-491
    • Schot, B.W.1    Zijlstra, J.M.2    Sluiter, W.J.3
  • 33
    • 0038702514 scopus 로고    scopus 로고
    • An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
    • Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667-678.
    • (2003) Bone Marrow Transplant , vol.31 , pp. 667-678
    • Peniket, A.J.1    Ruiz de Elvira, M.C.2    Taghipour, G.3
  • 34
    • 9444272217 scopus 로고    scopus 로고
    • Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry
    • Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104:3797-3803.
    • (2004) Blood , vol.104 , pp. 3797-3803
    • Freytes, C.O.1    Loberiza, F.R.2    Rizzo, J.D.3
  • 35
    • 20444410110 scopus 로고    scopus 로고
    • Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    • Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet 2005; 365:1934-1941.
    • (2005) The Lancet , vol.365 , pp. 1934-1941
    • Peggs, K.S.1    Hunter, A.2    Chopra, R.3
  • 36
    • 38649089434 scopus 로고    scopus 로고
    • Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    • Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455-462.
    • (2008) J Clin Oncol , vol.26 , pp. 455-462
    • Sureda, A.1    Robinson, S.2    Canals, C.3
  • 38
    • 34447573999 scopus 로고    scopus 로고
    • Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
    • Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764-2769.
    • (2007) J Clin Oncol , vol.25 , pp. 2764-2769
    • Ansell, S.M.1    Horwitz, S.M.2    Engert, A.3
  • 39
    • 0042738861 scopus 로고    scopus 로고
    • cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    • Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102:1458-1465.
    • (2003) Blood , vol.102 , pp. 1458-1465
    • Francisco, J.A.1    Cerveny, C.G.2    Meyer, D.L.3
  • 40
    • 53049084469 scopus 로고    scopus 로고
    • A novel antibody-drug conjugate, SNG-35 (Anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: Preliminary results of a phase I tolerability study
    • abstract PO99bis
    • Younes A, Forero-Torres A, Bartlett NL, et al. A novel antibody-drug conjugate, SNG-35 (Anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: preliminary results of a phase I tolerability study. Haematologica 2007; 92:64; abstract PO99bis.
    • (2007) Haematologica , vol.92 , pp. 64
    • Younes, A.1    Forero-Torres, A.2    Bartlett, N.L.3
  • 41
    • 34447566086 scopus 로고    scopus 로고
    • Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206
    • Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48:1313-1319.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1313-1319
    • Blum, K.A.1    Johnson, J.L.2    Niedzwiecki, D.3
  • 42
    • 34548542892 scopus 로고    scopus 로고
    • A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    • 441s; abstract 8000
    • Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007; 25:441s; abstract 8000.
    • (2007) J Clin Oncol , vol.25
    • Younes, A.1    Fanale, M.2    Pro, B.3
  • 43
    • 33644836549 scopus 로고    scopus 로고
    • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    • O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24:166-173.
    • (2006) J Clin Oncol , vol.24 , pp. 166-173
    • O'Connor, O.A.1    Heaney, M.L.2    Schwartz, L.3
  • 44
    • 33644832050 scopus 로고    scopus 로고
    • A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma
    • Kuruvilla J, Song K, Mollee P, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006; 11:25-29.
    • (2006) Hematology , vol.11 , pp. 25-29
    • Kuruvilla, J.1    Song, K.2    Mollee, P.3
  • 45
    • 0033013787 scopus 로고    scopus 로고
    • Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease
    • Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776-783.
    • (1999) J Clin Oncol , vol.17 , pp. 776-783
    • Diehl, V.1    Sextro, M.2    Franklin, J.3
  • 46
    • 38649125204 scopus 로고    scopus 로고
    • Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group
    • Nogova L, ReinekeT, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434-439.
    • (2008) J Clin Oncol , vol.26 , pp. 434-439
    • Nogova, L.1    Reineke, T.2    Brillant, C.3
  • 47
    • 34250793304 scopus 로고    scopus 로고
    • Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma
    • Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007; 110:179-185.
    • (2007) Cancer , vol.110 , pp. 179-185
    • Mauz-Korholz, C.1    Gorde-Grosjean, S.2    Hasenclever, D.3
  • 48
    • 38049162295 scopus 로고    scopus 로고
    • Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
    • Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109 - 111.
    • (2008) Blood , vol.111 , pp. 109-111
    • Schulz, H.1    Rehwald, U.2    Morschhauser, F.3
  • 49
    • 34250698040 scopus 로고    scopus 로고
    • Nodular lymphocyte-predominant Hodgkin lymphoma
    • Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 2007; 17:184-189.
    • (2007) Semin Radiat Oncol , vol.17 , pp. 184-189
    • Tsai, H.K.1    Mauch, P.M.2
  • 50
    • 27144479926 scopus 로고    scopus 로고
    • Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)
    • Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16:1683-1687.
    • (2005) Ann Oncol , vol.16 , pp. 1683-1687
    • Nogova, L.1    Reineke, T.2    Eich, H.T.3
  • 51
    • 51649083254 scopus 로고    scopus 로고
    • Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD)
    • abstract 644
    • Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood 2007; 110:198a; abstract 644.
    • (2007) Blood , vol.110
    • Horning, S.J.1    Bartlett, N.L.2    Breslin, S.3
  • 52
    • 0030747027 scopus 로고    scopus 로고
    • Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease
    • Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15:3060-3066.
    • (1997) J Clin Oncol , vol.15 , pp. 3060-3066
    • Bodis, S.1    Kraus, M.D.2    Pinkus, G.3
  • 53
    • 34250703560 scopus 로고    scopus 로고
    • Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
    • Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25:43-49.
    • (2007) J Clin Oncol , vol.25 , pp. 43-49
    • Heidenreich, P.A.1    Schnittger, I.2    Strauss, H.W.3
  • 54
    • 27244437759 scopus 로고    scopus 로고
    • Stroke as a late treatment effect of Hodgkin's disease: A report from the Childhood Cancer Survivor Study
    • Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508-6515.
    • (2005) J Clin Oncol , vol.23 , pp. 6508-6515
    • Bowers, D.C.1    McNeil, D.E.2    Liu, Y.3
  • 55
    • 33645460241 scopus 로고    scopus 로고
    • Stroke as a late treatment effect of Hodgkin's disease
    • Dorresteijn LD, Stewart FA, Boogerd W. Stroke as a late treatment effect of Hodgkin's disease. J Clin Oncol 2006; 24:1480.
    • (2006) J Clin Oncol , vol.24 , pp. 1480
    • Dorresteijn, L.D.1    Stewart, F.A.2    Boogerd, W.3
  • 56
    • 34047137002 scopus 로고    scopus 로고
    • American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography
    • Saslow D, Boetes C, Burke W, et al. American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89.
    • (2007) CA Cancer J Clin , vol.57 , pp. 75-89
    • Saslow, D.1    Boetes, C.2    Burke, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.